Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Marj P. Zimmerman, BSPharm, MS
President
RxDirections
Bucyrus, KS
Authored Items
Is a Biologic Produced 15 Years Ago a Biosimilar of Itself Today?
Stanton R. Mehr
,
Marj P. Zimmerman, BSPharm, MS
December 2016 Vol 9, No 9
in
Biosimilars
Reviewing the Unmet Needs of Patients with Multiple Sclerosis
Stanton R. Mehr
,
Marj P. Zimmerman, BSPharm, MS
November 2015 Vol 8, No 8
in
Original Research
How Do PCSK9 Inhibitors Stack Up to Statins for Low-Density Lipoprotein Cholesterol Control?
Marj P. Zimmerman, BSPharm, MS
November 2015 Vol 8, No 8
in
Original Research
Last modified: December 19, 2016
